Compare Manulife Financial Corporation (MFC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs Sana Biotechnology Inc — how do they compare? Manulife Financial Corporation trades at $43.84 (market cap $72.78B), while Sana Biotechnology Inc trades at $3.8 (market cap $1.13B). The key difference: Manulife Financial Corporation is far larger — about 64.4× Sana Biotechnology Inc's market cap, and Manulife Financial Corporation pays a 3.11% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| MFC | SANA | |
|---|---|---|
Market Cap | $72.78B | $1.13B |
Sector | Financials | Health |
52-Week High | $44.77 | $5.92 |
52-Week Low | $30.06 | $2.68 |
Enterprise Value | $67.92B | $1.05B |
Dividend Yield | 3.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MFC trades at $43.88, down 0.61% on the day, with a neutral technical signal despite bullish moving averages. The company reported Q2 2026 EPS of $0.79, beating estimates, driven by 21% APE sales growth in Asia. Revenue reached $53.01B in 2025, with net income margin at 11.7%. Recent news highlights AI partnerships with Microsoft and Alibaba Cloud, enhancing operational efficiency.
Outlook is positive with 57% analyst buy ratings and a $51.50 consensus target, though premium valuation (P/E 16.57) and mixed earnings history pose risks. Strengths include robust cash flow and dividend consistency, but investors face headwinds from competitive pressures and regulatory scrutiny in Asian markets.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
